P93.0
Grey baby syndrome
Clinical Classification Guidelines
Inclusion Terms
- Grey syndrome from chloramphenicol administration in newborn
Medical Intelligence & Overview
Grey Baby Syndrome is a rare but serious reaction that can occur in newborns and infants after the administration of the antibiotic chloramphenicol. Characterized by a distinctive greyish skin coloration, this condition results from an inability to properly metabolize and eliminate the drug, leading to toxic accumulation. Recognized under ICD-10 code P93.0, Grey Baby Syndrome requires prompt medical attention to prevent severe complications and ensure the safety of the young patient.
Causes & Symptoms
Clinical Causes: Administration of chloramphenicol to newborns and infants, especially those with immature liver function Reduced capacity of newborns' liver enzymes to metabolize the drug effectively High doses or prolonged use of chloramphenicol Underlying genetic factors affecting drug metabolism Concurrent illnesses affecting liver function
Key Symptoms: Bluish or greyish skin coloration (cyanosis or grey pigmentation) Vomiting and diarrhea Lethargy and weakness Hypotension (low blood pressure) Cyanosis (bluish tint around lips and fingertips) Respiratory distress Poor feeding or refusal to eat Low body temperature (hypothermia) Potential for circulatory collapse if untreated
Diagnostic & Treatment
Diagnosis Path: Diagnosis of Grey Baby Syndrome is primarily clinical, based on the characteristic symptoms and recent exposure to chloramphenicol. Laboratory tests can assist in confirming the diagnosis and assessing the extent of toxicity, including:
Treatment Protocols: Treatment focuses on supportive care and removing the offending agent. Important aspects include:
Clinical Advice & FAQs
Billing Guidance
Is P93.0 a billable ICD-10 code?
Yes, P93.0 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report P93.0?
Clinical documentation must specify the nature of Grey baby syndrome and any associated comorbidities for accurate reporting.
Cite this Clinical Reference